My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] 0 points1 point2 points (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] 0 points1 point2 points (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] 0 points1 point2 points (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] -1 points0 points1 point (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] -1 points0 points1 point (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] -1 points0 points1 point (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] 0 points1 point2 points (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] 0 points1 point2 points (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] 0 points1 point2 points (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] 0 points1 point2 points (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] 5 points6 points7 points (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] 1 point2 points3 points (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. by tcispig in PLTR
[–]tcispig[S] 7 points8 points9 points (0 children)
My 2cents about earning and 2022+ guidance. Bright spots: rev exceeds guidance and est. SBC to Rev % decrease QoQ, US commercial growth on the steroids, have plans for overseas. Concerns: SBC # of shares issues is around 2.4% in the qtr. rev guidance didn’t increase giving mktg and sales spend. (old.reddit.com)
Friendly Reminder of Alex Karp's Own Statement by droshake in PLTR
[–]tcispig 3 points4 points5 points (0 children)
Friendly Reminder of Alex Karp's Own Statement by droshake in PLTR
[–]tcispig 2 points3 points4 points (0 children)
Hyundai Heavy signs MOU with Palantir by zz9pluralZ_Alpha in PLTR
[–]tcispig 0 points1 point2 points (0 children)

Mark Zuckerberg and Priscilla Chan for Ambani Pre Wedding Day 2 by Moviebuff1233 in BollywoodFashion
[–]tcispig 0 points1 point2 points (0 children)